Literature DB >> 30350112

A realistic human skin model to study benzo[a]pyrene cutaneous absorption in order to determine the most relevant biomarker for carcinogenic exposure.

Etienne Bourgart1, Damien Barbeau1,2, Marie Marques1, Anne von Koschembahr3, David Béal3, Renaud Persoons1,2, Marie-Thérèse Leccia4, Thierry Douki3, Anne Maitre5,6.   

Abstract

Polycyclic aromatic hydrocarbons (PAH) are ubiquitous pollutants, among which benzo[a]pyrene (B[a]P) is the only compound classified carcinogenic to humans. Besides pulmonary uptake, skin is the major route of PAH absorption during occupational exposure. Health risk due to PAH exposure is commonly assessed among workers using biomonitoring. A realistic human ex vivo skin model was developed to explore B[a]P diffusion and metabolism to determine the most relevant biomarker following dermal exposure. Three realistic doses (0.88, 8.85 and 22.11 nmol/cm2) were topically applied for 8, 24, and 48 h. B[a]P and its metabolites were quantified by liquid chromatography coupled with fluorimetric detection. The impact of time, applied dose, and donor age were estimated using a linear mixed-effects model. B[a]P vastly penetrated the skin within 8 h. The major metabolites were 3-hydroxybenzo[a]pyrene (3-OHB[a]P) and 7,8,9,10-tetrahydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (B[a]P-tetrol). This latter predominantly derives from the most carcinogenic metabolite of B[a]P, benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE), as well as benzo[a]pyrene-9,10-diol-7,8-epoxide (reverse-BPDE). Benzo[a]pyrene-trans-7,8-dihydrodiol (B[a]P-7,8-diol) was a minor metabolite, and benzo[a]pyrene-trans-4,5-dihydrodiol (B[a]P-4,5-diol) was never quantified. Unmetabolized B[a]P bioavailability was limited following dermal exposure since less than 3% of the applied dose could be measured in the culture medium. B[a]P was continuously absorbed and metabolized by human skin over 48 h. B[a]P-tetrol production became saturated as the applied dose increased, while no effect was measured on the other metabolic pathways. Age had a slight positive effect on B[a]P absorption and metabolism. This work supports the relevance of B[a]P-tetrol to assess occupational exposure and carcinogenic risk after cutaneous absorption of B[a]P.

Entities:  

Keywords:  Benzo[a]pyrene; Biomonitoring; Cutaneous absorption; Ex vivo human skin model; Metabolism; Polycyclic aromatic hydrocarbons

Mesh:

Substances:

Year:  2018        PMID: 30350112     DOI: 10.1007/s00204-018-2329-2

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  4 in total

1.  Exposure assessment of polycyclic aromatic hydrocarbons in refined coal tar sealant applications.

Authors:  Seth McCormick; John E Snawder; I-Chen Chen; Jonathan Slone; Antonia M Calafat; Yuesong Wang; Lei Meng; Marissa Alexander-Scott; Michael Breitenstein; Belinda Johnson; Juliana Meadows; Cheryl Fairfield Estill
Journal:  Int J Hyg Environ Health       Date:  2022-04-25       Impact factor: 7.401

Review 2.  Dermal Exposure to Hazardous Chemicals in Baby Diapers: A Re-Evaluation of the Quantitative Health Risk Assessment Conducted by The French Agency for Food, Environmental and Occupational Health and Safety (ANSES).

Authors:  Alfred Bernard
Journal:  Int J Environ Res Public Health       Date:  2022-03-31       Impact factor: 3.390

Review 3.  Exposure to PAHs during Firefighting Activities: A Review on Skin Levels, In Vitro/In Vivo Bioavailability, and Health Risks.

Authors:  Gabriel Sousa; Joana Teixeira; Cristina Delerue-Matos; Bruno Sarmento; Simone Morais; Xianyu Wang; Francisca Rodrigues; Marta Oliveira
Journal:  Int J Environ Res Public Health       Date:  2022-10-04       Impact factor: 4.614

4.  Commensal-Related Changes in the Epidermal Barrier Function Lead to Alterations in the Benzo[a]Pyrene Metabolite Profile and Its Distribution in 3D Skin.

Authors:  Lisa Lemoine; Dilan Bayrambey; Alexander Roloff; Christoph Hutzler; Andreas Luch; Tewes Tralau
Journal:  mBio       Date:  2021-09-28       Impact factor: 7.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.